During the past decade, Azienda Ospedaliera Universitaria Senese conducted 127 clinical trials. In the 10-year time frame, 127 clinical trials started and 53 clinical trials were completed, i.e. on average, 41.7% percent of trials that started reached the finish line to date. In the past 5 years, 67 clinical trials started and 40 clinical trials were completed. i.e. 59.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Azienda Ospedaliera Universitaria Senese" #1 sponsor was "Hoffmann-La Roche" with 17 trials, followed by "Boehringer Ingelheim" with 13 trials sponsored, "University of Siena" with 13 trials sponsored, "Incyte Corporation" with 8 trials sponsored and "Philogen S.p.A." with 8 trials sponsored. Other sponsors include 115 different institutions and companies that sponsored additional 77 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Azienda Ospedaliera Universitaria Senese" #1 collaborator was "Bristol-Myers Squibb" with 3 trials as a collaborator, "Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte" with 3 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 3 trials as a collaborator, "Merck Sharp & Dohme LLC" with 3 trials as a collaborator and "Eli Lilly and Company" with 2 trials as a collaborator. Other collaborators include 24 different institutions and companies that were collaborators in the rest 32 trials.

According to Clinical.Site data, the most researched conditions in "Azienda Ospedaliera Universitaria Senese" are "Idiopathic Pulmonary Fibrosis" (12 trials), "Melanoma" (12 trials), "Metastatic Melanoma" (5 trials), "Periodontitis" (5 trials) and "Advanced Non-Small Cell Lung Cancer" (3 trials). Many other conditions were trialed in "Azienda Ospedaliera Universitaria Senese" in a lesser frequency.

Most popular intervention types in "Azienda Ospedaliera Universitaria Senese" are "Drug" (132 trials), "Other" (16 trials), "Device" (12 trials), "Biological" (11 trials) and "Procedure" (10 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (28 trials), "Rituximab" (8 trials), "Nintedanib" (6 trials), "Nivolumab" (6 trials) and "Avelumab" (4 trials). Other intervention names were less common.

The vast majority of trials in "Azienda Ospedaliera Universitaria Senese" are 175 trials for "All" genders and 4 trials for "Female" genders.

Currently, there are NaN active trials in "Azienda Ospedaliera Universitaria Senese". 1 are not yet recruiting, 39 are recruiting, 27 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 76 completed trials in Azienda Ospedaliera Universitaria Senese, 1 suspended trials, and 21 terminated clinical trials to date.

Out of the total trials that were conducted in Azienda Ospedaliera Universitaria Senese, 19 "Phase 1" clinical trials were conducted, 55 "Phase 2" clinical trials and 73 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 8 trials that are defined as “Not Applicable".

Azienda Ospedaliera Universitaria Senese has several departments that took part in Clinical trials: "U.O.C. Ematologia e Trapianti - A.O. Senese - Policlinico " Le Scotte"" - 18 trials, "Azienda Ospedaliera Universitaria Senese, U.O.C. Immunoterapia Oncologica" - 10 trials, "Aou Senese - Uoc Ematologia E Trapianti" - 39 trials, "Rheumatology Unit Azienda Ospedaliera Universitaria Senese" - 4 trials, "ospedale le scotte-U.O.C. Immunoterapia Oncologica" - 3 trials, "Aou Senese Ospedale S. Maria Alle Scotte - U.O.C. Cardiologia Ospedaliera" - 2 trials, "U.O. di Neuropsichiatria Infantile Azienda Ospedaliera Universitaria Senese" - 2 trials, "A.O. Universitaria Senese Oncologia Medica" - 2 trials